KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt to Equity (2019 - 2025)

Royalty Pharma's Debt to Equity history spans 7 years, with the latest figure at $0.92 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 25.18% year-over-year to $0.92; the TTM value through Dec 2025 reached $0.92, up 25.18%, while the annual FY2025 figure was $0.92, 25.18% up from the prior year.
  • Debt to Equity for Q4 2025 was $0.92 at Royalty Pharma, down from $0.93 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.93 in Q3 2025 and bottomed at $0.57 in Q2 2021.
  • The 5-year median for Debt to Equity is $0.72 (2023), against an average of $0.72.
  • The largest annual shift saw Debt to Equity decreased 18.56% in 2023 before it rose 25.39% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.7 in 2021, then rose by 6.28% to $0.75 in 2022, then fell by 18.56% to $0.61 in 2023, then increased by 20.98% to $0.74 in 2024, then rose by 25.18% to $0.92 in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Debt to Equity are $0.92 (Q4 2025), $0.93 (Q3 2025), and $0.84 (Q2 2025).